
ESOCAP HOLDS AN ADVISORY BOARD MEETING ON EOSINOPHILIC ESOPHAGITIS

Basel, Switzerland, December 1, 2020

EsoCap AG organized a scientific advisory board meeting with eleven international experts in Eosinophilic Esophagitis (EoE) in a digital format on December 1, 2020.

Three distinguished experts gave keynote presentations regarding the study of healthy volunteers conducted using the EsoCap system at the University of Greifswald, followed by EsoCap technology in the context of the latest EoE developments, and the upcoming ACESO clinical study of EoE.

The participants in this scientific advisory board meeting included eleven distinguished gastroenterologists from the EU, Switzerland and the USA, all internationally recognized for their expertise in EoE. The presentations were followed by an insightful discussion with the experts.

“I am greatly impressed by the wealth of expertise shared in this meeting”, said Dr Werner Tschollar, Chairman of the Board of EsoCap. “We are committed to working closely with the EoE experts to initiate the ACESO clinical trial rapidly.”



About EsoCap

EsoCap AG is a privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a unique topical drug delivery platform.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short transit times with less than two seconds from the mouth to the stomach.

EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocapbiotech.com.

Contact:

Isabelle Racamier, CEO

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com